Govt unveils Indian Pharmacopoeia reference substance for Enoxaparin Sodium for Bioassays

image credit- pib

The Indian Pharmacopoeia Commission (IPC), an autonomous body under the Ministry of Health and Family Welfare, Government of India, recently organised a two-day national conference on "Quality and Safety of Biosimilars: Strengthening India's Biopharma Shakti (SHAKTI) Vision" at the Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru.

A major highlight of the conference was the release of the Indian Pharmacopoeia Reference Substance (IPR) for Enoxaparin Sodium for Bioassays. Enoxaparin Sodium is a low molecular weight heparin and anticoagulant widely used for the prevention and treatment of thromboembolic disorders.

The IPR for Enoxaparin Sodium for Bioassays can serve as a certified reference material for bioassay testing, helping to ensure accurate, consistent, and comparable evaluation of its biological activity.

This release of the IPR is a significant step towards strengthening the availability of certified Pharmacopoeia Reference Substances for Bioassays related to Enoxaparin Sodium. It will also contribute to the vision of Atmanirbhar Bharat by strengthening India's indigenous drug quality infrastructure.

The conference was organised by the Indian Pharmaceutical Commission (IPC) in collaboration with the Indian Drug Manufacturers Association (IDMA). The Biotechnology Industry Research Assistance Council (BIRAC) and the Centre for Cellular and Molecular Platforms (C-CAMP) served as knowledge partners, while the Karnataka Drugs and Pharmaceuticals Manufacturers Association (KDPMA) was the associate partner.